Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442257 in Relapsed and Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
NCT04401020Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Jul 2020
- Primary completion
- Mar 2024
- Modality
- Trispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of SAR442257 in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), sponsored by Sanofi. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 4 months. Started Jul 2020; status: terminated.
02
Drugs
SAR442257
03
Conditions
multiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04401020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04401020.